CSL Limited has announced the Therapeutic Goods Administration approval for its Idelvion (albutrepenonacog alfa) for the treatment of patients with haemophilia B (congenital factor IX deficiency).
Idlevion is the first and only factor IX therapy for the treatment and prevention of bleeding in these patients, delivering high level protection with up to 14-day dosing.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Oct 16
